High burden of breast cancer in Belgium: Recent trends in incidence (1999-2006) and historical trends in mortality (1954-2006)

Archives of Public Health

Volumn 69, Issue 1, 2011, Pages 1-11

  Renard, Françoise ^a   Van Eycken, Liesbet ^a   Arbyn, Marc ^b  

^a Belgian Cancer Registry   (Belgium)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856808551     PISSN: 07787367     EISSN: None     Source Type: Journal    
DOI: 10.1186/0778-7367-69-2     Document Type: Article

References (52)

1. Bray F, McCarron P, Parkin DM: The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004, 6(T6):229-239.
2. Kelsey JL, Gammon MD, John EM: Reproductive factors and breast cancer. Epidemiol Rev 1993, 15(1):36-47.
3. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G: Breast cancer. Lancet 2005, 365(9472):1727-1741.
4. Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362(9382):419-427.
5. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003, 289(24):3243-3253.
6. Ferlay J, Bray F, Pisani P, Parkin M: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: IARC Press 2004.
7. Van Eycken E, De Wever N: Cancer incidence and survival in Flanders; 2000-2001. Brussels: Flemish Registry Network, VLK; 2006.
8. Belgian Cancer Registry Foundation. Yearly Statistics of cancer in Belgium. 2010 [http://www.registreducancer.be/.].
9. Ferlay J, Shin HR, Forman D, Mathers C, Parkin DM: Globocan. Cancer Incidence and Mortality Worldwide in 2008: IARC CancerBase. 10 ed. Lyon: IARC. 2010.
10. Perry N, Broeders M, de WC, Tornberg S, Holland R, von KL: European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition-summary document. Ann Oncol 2008, 19(4):614-622.
11. Jatoi I, Miller AB: Why is breast-cancer mortality declining? Lancet Oncol 2003, 4(4):251-254
12. Autier P, Boniol M, LaVecchia C, Vatten L, Gavin A, Hery C, et al: Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ 2010, 341: c3620.
13. Botha JL, Bray F, Sankila R, Parkin DM: Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003, 39(12):1718-1729.
14. Arbyn M, Capet F, Abarca M: Trends of breast cancer mortality in Belgium. Brussels: Scientific Institute of Public Health; 2002.
15. Arbyn M, Van Oyen H: Cervical cancer screening in Belgium. Eur J Cancer 2000, 36(17):2191-2197.
16. Belgian Cancer Registry Foundation. Cancer Incidence in Belgium 2004-2005. Brussels; 2008.
17. Renard F: The Belgian Cancer registry, current state and epidemiological perspectives. Annales de l'Association Belge de Radioprotection. 2009, 34(2):158-171.
18. Sobin L, Wittekind C: TNM Classification Malignant Tumors. New York: John Wiley & Sons;, 5 1997.
19. Sobin L, Wittekind C: TNM Classification Malignant Tumors. Washington: John Wiley & Sons;, 6 2002.
20. Curado M, Edwards B, Shin H, Ferlay J, Heanue M, Boyle P: Cancer Incidence in Five Continents. IARC Scientific Publication n°160 ed. Lyon: IARC; 2007.
21. Direction générale Statistique et Information économique (DGSIE). Causes de décès 1998, 1999 et 2004. 2009 [http://statbel.fgov.be/fr/modules/publications/statistiques/population/causes_de_deces.jsp].
22. Observatoire de la Santé et du Social de Bruxelles. Bulletins statistiques de décès. 2008.
23. Vlaams Agentschap Zorg en Gezondheid. Vlaamse gezondheidsindicatoren. Statistiek van de doodsoorzaken. 2008 [http://www.zorg-en-gezondheid.be/cijfers.aspx].
24. Segi M, Fujisaku S, Kurihama M, Naray Y, Sasajima K: The age-adjusted death rates for malignant neoplasms in some selected sites in 23 countries in 1954-1955 and their geographical correlation. Tohoku J Exp Med; 1960:72:91-103.
25. Jensen O, Parkin D, MacLennan R, Muir C, Skoog L: Enregistrement des Cancers, principes et méthodes. Lyon: IARC; 1996.
26. Hery C, Ferlay J, Boniol M, Autier P: Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol 2008, 19(6):1187-1194.
27. Who Mortality database. 2007 [http://www.who.int/whosis/mort/download/en/index.html].
28. Parkin D, Whelan S, Ferlay J, Teppo L, Thomas BA: Cancer incidence in five continents. Lyon: IARC scientific publications;, 8 20028.
29. Eurocim Version 4.1. European Incidence Database, European Network of Cancer registries. Lyon, France: IARC Press; 2003.
30. Kupper LL, Janis JM, Karmous A, Greenberg BG: Statistical age-periodcohort analysis: a review and critique. J Chronic Dis 1985, 38(10):811-830.
31. Arbyn M, Van Oyen H, Sartor F, Tibaldi F, Molenberghs G: Decsription of the influence of age, period and cohort effects on cervical cancer mortality by loglinear Poisson models (Belgium, 1955-1994). Arch Publ Health 2002, 60:73-100.
32. Kim HJ, Fay MP, Feuer EJ, Midthune DN: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000, 19(3):335-351.
33. Lerman PM: Fitting segmented regression models by grid search. Applied Statistics; 1980:29:77-84.
34. Van Hemelrijck MJ, Kabir Z, Connolly GN: Trends in lung cancer death rates in Belgium and The Netherlands: a systematic analysis of temporal patterns. J Community Health 2009, 34(3):188-194.
35. National Cancer Institute. Jointpoint Regression Program, version 3.4.3. 2010 [http://www.srab.cancer.gov/joinpoint/].
36. Hery C, Ferlay J, Boniol M, Autier P: Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol 2008, 19(6):1187-1194.
37. Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD: Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ 2005, 83(3):171-177.
38. Directorate General of Health and Consumers. Health Status indicators. European Union; 2011 [http://ec.europa.eu/health/indicators/indicators/index_en.htm].
39. Direction générale Statistique et Information économique (DGSIE) -Direction Thématique Société. Taux de fécondité selon l'âge des femmes atteint dans l'année, de 15 à 49 ans, Belgique 1961 - 2006. 2008 [http://statbel.fgov.be/fr/statistiques/chiffres/population/naissances_fecondite/indicateurs_de_fecondite/].
40. Renard F, Vankrunkelsven P, Van EL, Henau K, Boniol M, Autier P: Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. Ann Oncol 2010, 21(12):2356-2360.
41. IMS Health Belgium RdC61B. Drug sales in Belgium per three months. 2009.
42. van Duijnhoven FJ, van Gils CH, Bezemer ID, Peeters PH, van der Schouw YT, Grobbee DE: Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997. Maturitas 2006, 53(4):462-475.
43. Allemand H, Seradour B, Weill A, Ricordeau P: Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend. Bull Cancer 2008, 95(1):11-15.
44. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997, 350(9084):1047-1059.
45. Holli K, Isola J, Cuzick J: Hormone replacement therapy and biological aggressiveness of breast cancer. Lancet 1997, 350(9092):1704-1705.
46. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al: Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304(15):1684-1692.
47. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L: Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol 2007, 8(12):1129-1138.
48. Fabri V, Remacle A, Mertens R: Bilan de 6 ans de programme de dépistage du cancer du sein - 6ème rapport de l'Agence Intermutualiste. Agence intermutualiste 2009.
49. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F: Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005, 114(3):448-454.
50. Kumle M: Declining breast cancer incidence and decreased HRT use. Lancet 2008, 372(9639):608-610.
51. Katalinic A, Rawal R: Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008, 107(3):427-430.
52. Fontenoy AM, Leux C, Acour-Billon S, Allioux C, Frenel JS, Campone M, et al: Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: a decline since 2003. Cancer Epidemiol 2010, 34(3):238-243.